Stated investment advisor Saul Sterman, on Seeking Alpha, a stock market opinion and analysis website, Feb. 12
An article appearing in the L.A. Times reports on the growing controversy over the proposed mandatory vaccination of all teenage girls against cervical cancer. The two manufacturers of the vaccine are Merck and GlaxoSmithKline. At a cost of over $300 per recipient (3 x 100/120), should mandatory vaccination take hold in the U.S. and elsewhere, the two could realize revenue in excess of $250M a year each, until others develop competitive products....
[I]t may not be so simple to push this one through.... [I]t will take at least two decades before there is undisputed scientific evidence to confirm the vaccination's effectiveness in reducing mortality rates. Don't expect MRK and GSK to wait twenty years. They both have too much riding on this one.
